Patients with RA (n = 31) | Control group (n = 17) | p | ||
---|---|---|---|---|
Women | 58.1% (n = 18) | 41.2% (n = 7) | 0.367 | |
Age | 57 (48–61)a | 41 (29–68)a | 0.131 | |
BMI (kg/m2) | 25.8 (22.2–33)a | 24.0 (22.16–26.30)a | 0.343 | |
Medical history of smoking | 48.4% (n = 15) | 23.5% (n = 4) | 0.127 | |
Consumption (packets per year) | 20 (11–28)a | 0 (0–5)a | 0.094 | |
Recent RA ≤2 years | 32.3% (n = 10) | - | ||
Antibodies | ||||
RF+ | 74.2% (n = 23) | - | ||
ACPA+ | 80.6% (n = 25) | - | ||
Structural damage (erosions) | 41.9% (n = 13) | - | ||
NSAID | 12.9% (n = 4) | - | ||
Corticoids | 54.8% (n = 17) | - | ||
Median dosage (mg/day) | 5 (5–6)a | - | ||
Methotrexate | 64.5% (n = 20) | - | ||
Median dose (mg/week) | 15 (10–20)a | - | ||
Initiation (1st line of biomedicine) | 54.8% (n = 17) | - | ||
Abatacept | 38.7% (n = 12) | - | ||
Tocilizumab | 19.4% (n = 6) | - | ||
Anti-TNF drugs | Golimumab | 16.1% (n = 5) | - | |
Etanercept | 22.6% (n = 7) | - | ||
Certolizumab | 3.2% (n = 1) | - | ||
ESR (mm) | 14 (6–31)a | - | ||
CRP (mg/L) | 7.9 (3.0–23.2)a | - | ||
DAS28 | 4.24 (3.70–5.32)a | - | ||
DAS28-CRP | 4.42 (3.69–5.11)a | - | ||
HAQ | 1.63 (1–2)a | - |